ProNAi Therapeutics (NASDAQ:SRRA) Getting Somewhat Favorable News Coverage, Report Shows

Headlines about ProNAi Therapeutics (NASDAQ:SRRA) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.6294087146731 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of ProNAi Therapeutics (NASDAQ SRRA) traded down 0.316% during midday trading on Wednesday, reaching $1.575. The company had a trading volume of 84,775 shares. The stock’s 50 day moving average is $1.55 and its 200-day moving average is $1.55. The stock’s market capitalization is $82.32 million. ProNAi Therapeutics has a 12-month low of $1.31 and a 12-month high of $2.01.

ProNAi Therapeutics (NASDAQ:SRRA) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. On average, equities research analysts predict that ProNAi Therapeutics will post ($0.86) earnings per share for the current fiscal year.

SRRA has been the topic of a number of recent analyst reports. Jefferies Group LLC restated a “hold” rating on shares of ProNAi Therapeutics in a report on Thursday, July 27th. Zacks Investment Research raised ProNAi Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, ValuEngine raised ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. ProNAi Therapeutics presently has an average rating of “Hold” and an average target price of $3.25.

WARNING: “ProNAi Therapeutics (NASDAQ:SRRA) Getting Somewhat Favorable News Coverage, Report Shows” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://stocknewstimes.com/2017/09/20/pronai-therapeutics-srra-earns-coverage-optimism-score-of-0-20.html.

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for ProNAi Therapeutics (NASDAQ:SRRA)

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply